Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Adalimumab biosimilar by Biocon for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval
Adalimumab biosimilar is under clinical development by Biocon and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris). According to...
Data Insights
Adalimumab biosimilar by Aprogen for Autoimmune Disorders: Likelihood of Approval
Adalimumab biosimilar is under clinical development by Aprogen and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase...